Recent Quotes (30 days)

You have no recent quotes
chg | %

Pivotal Therapeutics Inc  

(Public, CNSX:PVO)   Watch this stock  
Find more results for PVO
-0.0100 (-12.50%)
Mar 26 - Close
CNSX real-time data - Disclaimer
Currency in CAD
Range 0.07 - 0.08
52 week 0.05 - 0.20
Open 0.08
Vol. 12,000.00
Mkt cap 6.54M
P/E     -
Div/yield     -
EPS -0.07
Shares 93.47M
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -2249.86% -975.77%
Operating margin -1513.50% -963.96%
EBITD margin - -945.34%
Return on average assets -166.03% -156.44%
Return on average equity - -1478.00%
CDP Score - -


81 Zenway Blvd Unit 10
+1-905-8569797 (Phone)
+1-905-8562177 (Fax)

Website links


Pivotal Therapeutics, Inc. is a Canada-based pharmaceutical company with a focus on cardiovascular health. The Company offers VASCAZENTM, is a prescription grade, ultra-pure Omega 3 fatty acid for the dietary management of cardiovascular disease in patients manifesting an Omega 3 fatty acid deficiency. VASCAZENTM is manufactured according to FDA (Food and Drug Administration) current Good Manufacturing Practices (cGMP) and each capsule of VASCAZENTM provides 680 mg of Eicosapentaenoic (EPA) and 110 mg of Eicosapentaenoic (EPA), for oral administration.

Officers and directors

Rachelle MacSweeney President, Director
Eugene G. Bortoluzzi Chief Executive Officer, Chief Financial Officer, Director
George Jackowski Ph.D. Chief Scientific Officer, Director
John S. Gebhardt Non-Executive Chairman of the Board
Age: 66
James J. Carey Independent Director
Giuseppe Simeone Independent Director